European life sciences investment firm Asabys Partners has integrated Aliath Bioventures, formerly Alta Life Sciences, in a deal that expands Asabys assets under management from $351 million to over $468 million. This strategic consolidation aims to build a life sciences investment platform exceeding €1 billion by 2030, targeting underserved segments including technology transfer, company creation, scale-ups, and growth-stage ventures across healthcare. The partnership brings strengthened capabilities and a shared investment philosophy, with the combined teams co-managing the Alta Life Sciences Spain I fund alongside global investors AltamarCAM Partners. Asabys co-founders Clara Campàs and Josep Sanfeliu anticipate this merger will accelerate portfolio expansion without disrupting investment strategies while enhancing project development capacity.